New drug combo opens for advanced GIST patients with no other options

NCT ID NCT06948955

First seen Nov 05, 2025 · Last updated May 16, 2026 · Updated 32 times

Summary

This program provides early access to an investigational drug called bezuclastinib, taken together with sunitinib, for people with advanced gastrointestinal stromal tumors (GIST) who have no other good treatment choices. The combination targets many types of KIT mutations that drive GIST. Participants must be 18 or older, able to swallow pills, and have tried or cannot tolerate imatinib.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTROINTESTINAL NEOPLASMS, GASTROINTESTINAL STROMAL TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Cleveland Clinic Foundation

    AVAILABLE

    Cleveland, Ohio, 44195, United States

    Contact Phone: •••-•••-••••

    Contact Phone: •••-•••-••••

  • Dana Farber Cancer Institute (DFCI)

    AVAILABLE

    Boston, Massachusetts, 02215, United States

    Contact Phone: •••-•••-••••

  • Huntsman Cancer Institute, University of Utah

    AVAILABLE

    Salt Lake City, Utah, 84112, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • MD Anderson Cancer Center

    AVAILABLE

    Houston, Texas, 77030, United States

    Contact Email: •••••@•••••

  • Mayo Clinic

    AVAILABLE

    Jacksonville, Florida, 32224, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Mayo Clinic

    AVAILABLE

    Rochester, Minnesota, 55905, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Mayo Clinic Hospital

    AVAILABLE

    Phoenix, Arizona, 85054, United States

    Contact Phone: •••-•••-••••

  • Memorial Sloan Kettering Cancer Center

    AVAILABLE

    New York, New York, 10065, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Orlando Health

    AVAILABLE

    Orlando, Florida, 32806, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Shenandoah Oncology

    AVAILABLE

    Winchester, Virginia, 22601, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Smillow Cancer Hospital - Yale New Haven Health

    AVAILABLE

    New Haven, Connecticut, 06510, United States

    Contact Email: •••••@•••••

  • Taylor Cancer Research Center

    AVAILABLE

    Maumee, Ohio, 43537, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center

    AVAILABLE

    Columbus, Ohio, 43210, United States

    Contact Email: •••••@•••••

  • The University of Chicago Medical Center

    AVAILABLE

    Chicago, Illinois, 60637, United States

    Contact Email: •••••@•••••

  • UCLA Department of Medicine- Hematology/Oncology

    AVAILABLE

    Los Angeles, California, 90095, United States

    Contact Email: •••••@•••••

  • UPMC Hillman Cancer Center

    AVAILABLE

    Pittsburgh, Pennsylvania, 15232, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • USC/Norris Comprehensive Cancer Center

    AVAILABLE

    Los Angeles, California, 90033, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Colorado

    AVAILABLE

    Aurora, Colorado, 80045, United States

    Contact Email: •••••@•••••

    Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.